+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Occurrence of the antibody against human papillomavirus type 16 virion protein L2 in patients with cervical cancer and dysplasia



Occurrence of the antibody against human papillomavirus type 16 virion protein L2 in patients with cervical cancer and dysplasia



Intervirology 38(3-4): 187-191



Infection with HPV 16 is believed to be a major risk factor for cervical cancer. To correlate HPV 16 infection and carcinogenesis in the cervix, we examined by ELISA 326 sera from healthy females and patients with cervical cancer, cervical intraepithelial neoplasia, or dysplasia, for the presence of IgG antibodies against HPV 16 virion protein L2 expressed in Escherichia coli. Whereas 2 of 208 were positive in the healthy females, 4 of 23 and 6 of 90 were positive in the patients with cervical cancer and dysplasia, respectively. The findings indicate that infection with HPV 16 is related to cancer and dysplasia of the cervix. The anti-L2 antibody did not occur coincidentally with the antibodies against the HPV 16 early proteins E4 and E7, which are specifically but independently associated with patients with cervical cancer.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046850120

Download citation: RISBibTeXText

PMID: 8682615


Related references

Serum antibody against unfused recombinant E7 protein of human papillomavirus type 16 in cervical cancer patients. Japanese Journal of Cancer Research 86(1): 28-34, 1995

Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations. Journal of Infectious Diseases 181(5): 1764-1767, 2000

Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. Journal of General Virology 77: 1585-1593, 1996

Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Research 69(10): 4407-4414, 2009

The impact of an imperfect vaccine and pap cytology screening on the transmission of human papillomavirus and occurrence of associated cervical dysplasia and cancer. Mathematical Biosciences and Engineering 10(4): 1173-1205, 2014

Correlation of human papillomavirus type 16 and human papillomavirus type 18 e7 messenger RNA levels with degree of cervical dysplasia. Cancer Epidemiology, Biomarkers and Prevention 14(8): 1948-1952, 2005

Human T cell responses to human papillomavirus type 16 in patients with cervical dysplasia and HPV-16 infection. Journal of Cellular Biochemistry Supplement 0(18B): 137, 1994

Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia. Journal of General Virology 77: 593-602, 1996

Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. Journal of Virology 73(7): 5402-5410, 1999

Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. Journal of Virology 77(9): 5464-5474, 2003

The E7 protein of human papillomavirus (HPV) type 16 expressed by recombinant vaccinia virus can be used for detection of antibodies in sera from cervical cancer patients. Journal of Virological Methods 62(1): 81-85, 1996

Detection of E2 gene polymorphism of human papillomavirus type 16 in patients with cervical lesions and cervical cancer. Nan Fang Yi Ke Da Xue Xue Bao 32(10): 1503-1506, 2013

Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls. Cancer Research 50(24): 7815-7819, 1990

Follow-up of antibody responses to human papillomavirus type 16 E7 in patients treated for cervical carcinoma. Journal Of Medical Virology. 45(3): 342-347, 1995

The prognostic role of serologic testing for antibody production against human papillomavirus type 16 E6 and E7 oncogenes in cervical cancer. Gynecologic Oncology 56(1): 138, 1995